Skip to main content

DaVita Value Stock - Dividend - Research Selection

Davita

ISIN: US23918K1088 , WKN: 897914

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market

2026-03-30
In the most recent trading session, DaVita HealthCare (DVA) closed at $152.37, indicating a -1.33% shift from the previous trading day.

Should Value Investors Buy DaVita (DVA) Stock?

2026-03-27
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is It Time To Reconsider DaVita (DVA) After Its Strong Three Year Share Price Run?

2026-03-24
If you are wondering whether DaVita's current share price lines up with its underlying worth, this breakdown will help you frame that question clearly. The stock most recently closed at US$152.21, with returns of 2.7% over 7 days, 1.0% over 30 days, 32.9% year to date, 1.2% over 1 year, 97.3% over 3 years and 38.3% over 5 years. Recent headlines around DaVita have kept attention on the stock, adding context to these return figures and shaping how investors think about risk and reward. This...

DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know

2026-03-23
DaVita HealthCare (DVA) reached $152.21 at the closing of the latest trading day, reflecting a +1.94% change compared to its last close.

AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE

2026-03-23
AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of February 28, 2026.

Wall Street Raises Outlook For Three AI Names And This Medical Stock

2026-03-23
Higher profit estimates from Wall Street for four stocks make them notable in Monday's stock market as they near buy points.

DaVita Stock: Is DVA Outperforming the Health Care Sector?

2026-03-20
DaVita has outperformed the Health Care sector recently, but analysts are cautious about the stock’s prospects.

DaVita’s Strong Operations Confront Debt Warning And Insider Selling Signals

2026-03-19
DaVita (NYSE:DVA) reports strong operational performance with solid revenue growth and expanding margins. The company now faces early warning signals, including a distress-level Altman Z-Score that flags potential financial risk. Recent insider selling activity at DaVita adds another layer of concern for investors tracking internal confidence. DaVita, a major provider of kidney care services, sits at the intersection of aging demographics, chronic disease trends and ongoing pressure on...

DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

2026-03-18
DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare

2026-03-18
DGX, DVA, OPCH and ADUS gain attention as telehealth, AI adoption and aging population drive growth in home healthcare services.